Stephanie Weiss, M.D., Ph.D., assistant director for the Clinical Research, Medication Development Program at NIDA, shared data from the first published clinical trial of GLP-1 RAs in alcohol use disorder: in patients with obesity with a BMI over 30, exenatide reduced heavy drinking days by 23.6% and lowered total alcohol intake
Key values to watch during this period include electrolytes, especially sodium and potassium, kidney function markers, and fasting glucose if applicable
For those curious about how it compares to other options or what side effects to expect, looking at user reviews for semaglutide and personal stories can be helpful
Khng dng li , glutathione cn l mt cht chng oxy ha mnh, gip trung ha cc gc t do t tia UV, nhim v stress, t giupd hn ch tng sinh melanin